Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218146 · ClinicalTrials.gov registry record · Phase 3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
A Phase 3 study of Small-cell Lung Cancer, sponsored by Zai Lab (Shanghai) Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 14
- Study locations
NCT07218146: Recruiting Phase 3 study of Small-cell Lung Cancer, sponsored by Zai Lab (Shanghai) Co..
NCT07218146 is a Phase 3 study of Small-cell Lung Cancer that is actively recruiting participants, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 480 participants, above the 226-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (112% higher). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218146, a Phase 3 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Zai Lab (Shanghai) Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Conditions Studied
Interventions
- DRUG ZL-1310
- DRUG Investigator's Choice of Therapy
Study Locations (14)
Florida
- Zai Lab Site 02045 - Clermont
- Zai Lab Site 02031 - Orange City
- Zai Lab Site 02020 - Rockledge
- Zai Lab Site 02026 - Sarasota
Illinois
- Zai Lab Site 02021 - Peoria
- Zai Lab Site 02049 - Peoria
Pennsylvania
- Zai Lab Site 02035 - Broomall
- Zai Lab Site 02019 - Media
Kentucky
- Zai Lab Site 02041 - Louisville
Maryland
- Zai Lab Site 02003 - Bethesda
Missouri
- Zai Lab Site 02023 - Columbia
Tennessee
- Zai Lab Site 02036 - Nashville
Texas
- Zai Lab Site 02025 - Odessa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-11-30 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 3 |
What NCT07218146 shows while recruiting
NCT07218146 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 226-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (112% higher).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which ZL-1310 is the first listed.
NCT07218146 lists 14 locations in 9 states (Florida, Illinois, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT07218146 about?
NCT07218146 is a clinical study titled "A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)". The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
What is the current status of trial NCT07218146?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-11-30. Estimated completion is 2028-11-30.
What conditions does trial NCT07218146 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT07218146?
The interventions under investigation include: ZL-1310 (DRUG), Investigator's Choice of Therapy (DRUG).
Who is sponsoring clinical trial NCT07218146?
This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218146 being conducted?
This trial has 14 study locations across Florida, Illinois, Kentucky, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07218146's enrollment target sits among peer trials
480 13th of 79 higher than 67 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI